7月10日,艾伯维宣布与Ichnos Glenmark Innovation的全资子公司IGI Therapeutics达成独家许可协议,获得其主要资产ISB 2001在北美、欧洲、日本和大中华区的独家开发、生产和商业化权益。根据协议条款,IGI Therapeutics将获得7亿美元的预付款,并有资格获得高达12.25亿美元的开发、监管和商业化里程碑付款,以及基于净销售额的两位数分层特许权使用费...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.